Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro
Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
16 December 2014
|
| In: |
Pharmaceutics
Year: 2014, Volume: 6, Issue: 4, Pages: 632-650 |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics6040632 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3390/pharmaceutics6040632 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4923/6/4/632 
|
| Author Notes: | Johanna Weiss, Dirk Theile, Zdenek Dvorak and Walter Emil Haefeli |
| Summary: | Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidrug resistant cells in vitro. |
|---|---|
| Item Description: | Gesehen am 16.10.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1999-4923 |
| DOI: | 10.3390/pharmaceutics6040632 |